Alvotech Ordinary Shares (ALVO)
Stock · NASDAQ · Health Care
$5.03as of 10/16/2026
Price chart
Active signals
ALVO Signal Track Record
How signals performed across all stocks →What ALVO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | +2.4% | 53% | October 5, 2026 |
| Bollinger Band BreakdownActive now | 20 | +1.7% | 55% | July 24, 2026 |
| Bollinger Band Breakout | 19 | +0.3% | 53% | September 18, 2026 |
| 200-Day Moving Average TouchActive now | 12 | -8.3% | 17% | May 30, 2025 |
| Any 20-session window (baseline) | -1.8% | 45% |
Computed by MarketWall from daily closing prices since April 3, 2023. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ALVO
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company provides AVT02, a high concentration, low-volume adalimumab formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis,…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 1,279
- Website
- www.alvotech.com/
Fundamentals
- 1-day range
- $4.95$5.27
- Market cap
- $1.19B
- P/E (trailing)
- —
- P/E (forward)
- 21.72
- EPS (trailing)
- $-0.63
- Dividend yield
- —
- Beta
- 0.22
- Avg. volume
- 1.08M
Forecasts
5 analyst ratings
Alvotech Ordinary Shares Competitors
Chosen by industry and closest market cap.
- ALVOAlvotech Ordinary Shares$5▼ 5.84%Market cap $1.19BP/E —$2.94$9.05
- MGTXMeiraGTx Holdings plc Ordinary Shares$9.28▼ 6.17%Market cap $1.18BP/E 11.93$6.62$15.35
- INBXInhibrx Biosciences Inc. Common Stock$89.83▼ 0.74%Market cap $1.26BP/E —$28.16$155.29
- IMTXImmatics N.V. Ordinary Shares$6.73▼ 5.74%Market cap $1.26BP/E —$6.73$12.41
- CGEMCullinan Therapeutics Inc. Common Stock$12.93▼ 7.64%Market cap $1.10BP/E —$6.73$23.19
- NVAXNovavax Inc. Common Stock$11.26▼ 12.17%Market cap $1.27BP/E —$6.2$13.39
- VORVor Biopharma Inc. Common Stock$18.03▼ 6.77%Market cap $1.28BP/E 1.82$6.5$33.42
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ALVO Alvotech Ordinary Shares | $1.19B | — | $5 | ▼ 5.84% | $2.94$9.05 |
| MGTX MeiraGTx Holdings plc Ordinary Shares | $1.18B | 11.93 | $9.28 | ▼ 6.17% | $6.62$15.35 |
| INBX Inhibrx Biosciences Inc. Common Stock | $1.26B | — | $89.83 | ▼ 0.74% | $28.16$155.29 |
| IMTX Immatics N.V. Ordinary Shares | $1.26B | — | $6.73 | ▼ 5.74% | $6.73$12.41 |
| CGEM Cullinan Therapeutics Inc. Common Stock | $1.10B | — | $12.93 | ▼ 7.64% | $6.73$23.19 |
| NVAX Novavax Inc. Common Stock | $1.27B | — | $11.26 | ▼ 12.17% | $6.2$13.39 |
| VOR Vor Biopharma Inc. Common Stock | $1.28B | 1.82 | $18.03 | ▼ 6.77% | $6.5$33.42 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Alvotech, Advanz Pharma File AVT29 Line Extension To Mynzepli Marketing Authorization With EMA For Proposed Eylea 8mg Biosimilarbenzinga · 10/14/2026
- Why This Biotech Stock Just Got a Rare Double UpgradeYahoo · 9/16/2026
- ALVO Stock Jumps On Double Upgrade — Why Barclays Sees A 59% UpsideYahoo · 9/16/2026
- Gapping stocks in Wednesday's sessionChartMill · 9/16/2026
- Alvotech Shares Rise 5.6% After Barclays Upgrades Rating and Doubles Price TargetYahoo · 9/16/2026
- LuxExperience, Alvotech, Twist Bioscience And Other Big Stocks Moving Higher On WednesdayBenzinga · 9/16/2026
- Rapport Therapeutics To Rally Around 76%? Here Are 10 Top Analyst Forecasts For WednesdayBenzinga · 9/16/2026
- This Union Pacific Analyst Turns Bullish; Here Are Top 5 Upgrades For WednesdayBenzinga · 9/16/2026
- Barclays Upgrades Alvotech to Overweight, Raises Price Target to $8Benzinga · 9/16/2026
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Alvotech signs US manufacturing deal with LOTTE Biologics
Alvotech has announced a manufacturing agreement with LOTTE Biologics to increase global supply from the United States. This move addresses capacity constraints and supports the company's operational expansion. The news coincides with the stock trading near its 52-week low, while analysts maintain an average price target of $6.80.
Alvotech signs US manufacturing deal with LOTTE Biologics. Alvotech has announced a manufacturing agreement with LOTTE Biologics to increase global supply from the United States. This move addresses capacity constraints and supports the company's operational expansion. The news coincides with the stock trading near its 52-week low, while analysts maintain an average price target of $6.80.